Preview

Вестник дерматологии и венерологии

Расширенный поиск

Розацеа: распространенность, патогенез, особенности клинических проявлений

https://doi.org/10.25208/0042-4609-2015-0-3-36-45

Полный текст:

Аннотация

В обзоре литературы рассматриваются основные аспекты распространенности розацеа в Российской Федерации и зарубежных странах. Представлен взгляд на патогенез и гистологическую картину розацеа, а также приведена актуальная классификация и ряд основных клинических форм заболевания.

Об авторах

А. А. Кубанова
ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Россия


Ю. Б. Махакова
ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России
Россия


Список литературы

1. Eckel R. Rosacea: the strawberry fields of dermatology. Prime Journal 2014; 4 (4): 60-62.

2. Steinhoff M., Schauber J., Leyden J. J. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol Elsevier 2013; 69: 15-26.

3. Zouboulis C. C., Katsambas A. D., Kligman A. M. Pathogenesis and Treatment of Acne and Rosacea. Berlin: Springer; 2014.

4. Rolleston J. D. A. Note on the Early History of Rosacea. Proc R Soc Med 1933; 26 (4): 327-329.

5. Barabanov L.G., Muzychenko A.P. Sovremennyy vzglyad na etiopatogenez rozatsea. ARS MEDICA 2010; (8): 124-128. [Барабанов Л.Г., Музыченко А.П. Современный взгляд на этиопатогенез розацеа // ARS MEDICA. 2010. № 8. 124-128].

6. Yutskovskaya Ya.A., Kusaya N.V., Klyuchnik S.B. Obosnovanie patogeneticheskoy terapii pri aknepodobnykh dermatozakh, oslozhnennykh kleshchevoy invaziey Demodex folliculorum. Klin dermatol i venerol 2010; (3): 60-63. [Юцковская Я.А., Кусая Н.В., Ключник С.Б. Обоснование патогенетической терапии при акнеподобных дерматозах, осложненных клещевой инвазией Demodex folliculorum. Клиническая дерматология и венерология. 2010. № 3. 60-63].

7. Kogan B.G., Golovchenko D.Ya. Sovremennye podkhody v kompleksnom lechenii patsientov s demodekozom i rozovymi ugryami. Klin imunol allergol infektol 2011; (1): 38-43. [Коган Б.Г., Головченко Д.Я. Современные подходы в комплексном лечении пациентов с демодекозом и розовыми угрями. Клин имунол аллергол инфектол 2011; (1): 38-43.]

8. Saydalieva V.Sh. Effektivnost' nizkikh doz izotretinoina pri lechenii bol'nykh papulo-pustuleznym podtipom rozatsea. Lechebnoe delo 2012; (2): 88-92. [Сайдалиева В.Ш. Эффективность низких доз изотретиноина при лечении больных папуло-пустулезным подтипом розацеа. Лечебное дело. Общество с ограниченной ответственностью «АТМО», 2012. № 2. 88-92].

9. Wollina U., Verma S. B. Rosacea and rhinophyma: not curse of the Celts but Indo Eurasians. J Cosmet Dermatol 2009; 8 (3): 234-235.

10. Berg M., Liden S. An epidemiological study of rosacea. Acta Derm Venerol 1989; 69 (5): 419-423.

11. Schaefer I., Rustenbach S. J., Zimmer L. et al. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008; (2): 169-172.

12. Abram K., Silm H., Oona M. Prevalence of rosacea in an Estonian working population using a standard classification. Acta Derm Venereol 2010; 90 (3): 269-273.

13. Two A. M., Del Rosso J. Q. Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol 2014; 7 (1): 20-25.

14. Bamford J. T. M., Gessert C. E., Renier C. M. et al. Childhood stye and adult rosacea. J Am Acad Dermatol 2006; 55: 951-955.

15. Romanowicz M., Stephenson J. J., Del Rosso J. Q. et al. Healthcare utilization and costs of patients with rosacea in an insured population. J Drugs Dermatol 2008; 7: 41-49.

16. Tan J., Berg M. Rosacea: Current state of epidemiology. J Am Acad Dermatol 2013; 69: 27-35.

17. Abram K., Silm H., Maaroos H. I. et al. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol 2010; 24 (5): 565-571.

18. Steinhoff M., Buddenkotte J., Aubert J. et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15 (1): 2-11.

19. Halder R. M., Brooks H. L., Callender V. D. Acne in ethnic skin. Dermatol Clin 2003; 21 (4): 609-615.

20. Khaled A., Hammami H., Zeglaoui F. et al. Rosacea: 244 Tunisian cases. Tunis Med 2010; 88 (8): 597-601.

21. Spoendlin J., Voegel J. J., Jick S. S. et al. A study on the epidemiology of rosacea in the U. K. Br J Dermatol 2012; 167: 598-605.

22. Kyriakis K. P., Palamaras I., Terzoudi S. et al. Epidemiologic aspects of rosacea. J Am Acad Dermatol 2005; 53 (5): 918-919.

23. Samodelkina K.A., Korotkiy N.G., T.V. M. Sovremennye kontseptsii etiologii i patogeneza rozatsea. Klin dermatol venerol 2012; (2): 4-8. [Самоделкина К.А., Короткий Н.Г., Т.В. М. Современные концепции этиологии и патогенеза розацеа. Клин дерматол венерол 2012; 2: 4-8].

24. Reinholz M., Tietze J. K., Kilian K. et al. Rosacea - S1 guideline. J Dtsch Dermatol Ges 2013: 11 (8): 768-780.

25. Böhm D., Schwanitz P., Stock Gissendanner S. et al. Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med 2014; 19 (5): 586-591.

26. Goldberg D. J., Berlin A. Acne and Rosacea: Epidemiology, Diagnosis and Treatment. London: CRC Press; 2011.

27. Zhang H., Liao W., Chao W. et al. Risk factors for sebaceous gland diseases and their relationship to gastrointestinal dysfunction in Han adolescents. J Dermatol 2008; 35: 555-561.

28. Kroshinsky D., Glick S. A. Pediatric rosacea. Dermatol Ther 2006; 19: 196-201.

29. Lacz N. L., Schwartz R. A. Rosacea in the pediatric population. Cutis 2004: 74: 99-103.

30. Kyriakis K. P. et al. Epidemiologic aspects of rosacea. J Am Acad Dermatol 2005; 53 (5): 918-919.

31. Lehmann P. Rosacea. Clinical features, pathogenesis and therapy. Hautarzt 2005; 56: 871-885.

32. Jansen T. Clinical presentations and classification of rosacea. Ann Dermatol Venereol 2011; 138: 192-200.

33. Powell F. C. Clinical practice. Rosacea. N Engl J Med 2005; 352 (8): 793-803.

34. Rolleston J. D. A. Note on the Early History of Rosacea. Proc R Soc Med 1933; 26 (4): 327-329.

35. Spoendlin J. A study on the epidemiology of rosacea. University of Basel 2013: 143.

36. Katunina O.R. Funktsii Toll-podobnykh retseptorov kak komponenta vrozhdennogo immuniteta i ikh uchastie v patogeneze dermatozov razlichnoy etiologii. Vestn dermatol venerol 2011; (2): 18-

37. [Катунина О.Р. Функции Toll-подобных рецепторов как компонента врожденного иммунитета и их участие в патогенезе дерматозов различной этиологии. Вестн дерматол венерол 2011; 2: 18-25.]

38. Valins W., Amini S., Berman B. The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators. J Clin Aesthet Dermatol 2010; 3 (9): 20-29.

39. Yamasaki K., Schauber J., Coda A. et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006; 20: 2068-2080.

40. Yamasaki K., Nardo A. D., Bardan A. et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007; 13: 975-980.

41. Davydova A.V. et al. Molekulyarnye mekhanizmy patogeneza rozatsea. Saratovskiy nauchnomeditsinskiy zhurnal 2013; 9 (3): 561-565. [Давыдова А.В. et al. Молекулярные механизмы патогенеза розацеа. Саратовский научно-медицинский журнал. Государственное образовательное учреждение высшего профессионального образования Саратовский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию, 2013; 9 (3): 561-565.]

42. Peric M., Koglin S., Kim S. M. et al. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol 2008; 181: 8504-8512.

43. Khayrutdinov V.R. Rozatsea: sovremennye predstavleniya o patogeneze, klinicheskoy kartine i lechenii. Effektivnaya farmakoterapiyа 2014; (3): 32-37. [Хайрутдинов В.Р. Ро-зацеа: современные представления о патогенезе, клинической картине и лечении. Эффективная фармакотерапия. 2014; 3: 32-37.]

44. Yamasaki K., Gallo R. L. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc 2011; 15 (1): 12-15.

45. Reinholz M., Ruzicka T., Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol 2012; 24 (2): 126-135.

46. Salzer S., Kresse S., Hirai Y., Koglin S., Ruzicka T., Schauber J. Cathelicidin peptide LL-37 increases UVB-triggered inflammasome activation: Possible implications for rosacea. J Derm Sci 2014; 76 (3): 173-179.

47. Koczulla R., von Degenfeld G., Kupatt C. et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003; 111 (11): 1665-1672.

48. Chen X., Niyonsaba F., Ushio H. et al. Human cathelicidin LL-37 increases vascular permeability in the skin via mast cell activation, and phosphorylates MAP kinases p38 and ERK in mast cells. J Dermatol Sci 2006; 43 (1): 63-66.

49. Elewski B. E., Draelos Z., Dréno B. et al. Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011; 25 (2): 188-200.

50. Antal A. S., Dombrowski Y., Koglin S. et al. Impact of vitamin D3 on cutaneous immunity and antimicrobial peptide expression. Dermatoendocrinol 2011; 3: 18-22.

51. Jones D. A. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthet Dermatol 2009; 2: 26-30.

52. Laquer V., Hoang V., Nguyen A. et al. Angiogenesis in cutaneous disease: Part II. J Am Acad Dermatol 2009; 61: 945-958.

53. Schauber J., Gallo R. L. The vitamin D pathway: A new target for control of the skin’s immune response? Exp Dermatol 2008; 17: 633-639.

54. Palatsi R., Kelhälä H.-L., Hägg P. [New insights in the pathogenesis and treatment of rosacea]. Duodecim 2012; 128: 2327-2335.

55. Yamasaki K., Kanada K., Macleod D. T. et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. The Society for Investigative Dermatology Inc 2011; 131 (3): 688-697.

56. Obgol'ts I.A., Nemchaninova O.B. Novye podkhody k terapii rozatsea. Sovrem probl dermatovenerol, immunol vrach kosmetol 2010; (4): 15-19. [Обгольц И.А., Немчанинова О.Б. Новые подходы к терапии розацеа. Современные проблемы дерматовенерологии, иммунологии и врачебной косметологии. 2010; 4: 15-19.]

57. Flint I. D., Wilkin J. K. Acquired persistent erythematous patch on the neck. Acquired nevus flammeus. Arch Dermatol 1994: 130 (4): 509, 512.

58. Drummond P. D., S. D. Blushing in rosacea sufferers. J Psychosom Res 2012; 72 (2): 153-8.

59. Gomaa A. H. A., Yaar M., Eyada M. M. et al. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol 2007; 34 (10): 748-753.

60. Olisova O.Yu., Dodina M.I., Kushlinskiy N.E. Rol' faktora rosta sosudistogo endoteliya v patogeneze rozatsea i ego medikamentoznaya korrektsiya. Klin dermatol i venerol 2012; (1): 49-55. [Олисова О.Ю., Додина М.И., Кушлинский Н.Е. Роль фактора роста сосудистого эндотелия в патогенезе розацеа и его медикаментозная коррекция. Клин дерматол венерол 2012; 1: 49-55.]

61. Wilkin J. K. Why is flushing limited to a mostly facial cutaneous distribution? J Am Acad Dermatol 1988; (19): 309-313.

62. Buechner S. A. Rosacea: An update. Dermatology 2005; 210: 100-108.

63. Diamantis S., Waldorf H. A. Rosacea: clinical presentation and pathophysiology. J Drugs Dermatol 2006; 5: 8-12.

64. Darlenski R., Kazandjieva J., Tsankov N. et al. Acute irritant threshold correlates with barrier function, skin hydration and contact hypersensitivity in atopic dermatitis and rosacea. Exp Dermatol 2013; 22: 752-753.

65. Meyer-Hoffert U., Schröder J.-M. Epidermal Proteases in the Pathogenesis of Rosacea. J Investig Dermatology Symp Proc 2011; 15: 16-23.

66. Voegeli R., Rawlings A. V., Doppler S. et al. Increased basal transepidermal water loss leads to elevation of some but not all stratum corneum serine proteases. Int J Cosmet Sci 2008; 30: 435-442.

67. Rios-Yuil J. M., Mercadillo-Perez P. Evaluation of Demodex folliculorum as a Risk Factor for the Diagnosis of Rosacea In Skin Biopsies. Mexico’s General Hospital (1975-2010). Indian J Dermatol 2013; 58: 157.

68. Holmes A. D. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol 2013; 69: 1025-1032.

69. Wollina U. Recent advances in the understanding and management of rosacea. F1000Prime Rep 2014; 6: 50.

70. Boixeda de Miquel D., Vazquez Romero M., Vazquez Sequeiros E. et al. Effect of Helicobacter pylori eradication therapy in rosacea patients. Rev Esp Enferm Dig 2006; 98: 501-509.

71. Herr H., You C. H. Relationship between Helicobacter pylori and rosacea: It may be a myth. J Korean Med Sci 2000; 15: 551-554.

72. Spoendlin J., Voegel J. J., Jick S. S. et al. Migraine, triptans, and the risk of developing rosacea: A population-based study within the United Kingdom. J Am Acad Dermatol 2013; 69: 399-406.

73. Spoendlin J., Schneider C., Jick S. S. et al. Migraine in patients with rosacea. Pharmacoepidemiol Drug Saf 2011; 20: 199-200.

74. Berg M., Lidén S. Postmenopausal female rosacea patients are more disposed to react with migraine. Dermatology 1996: 193 (1): 73-74.

75. Gupta M. A., Gupta A. K., Chen S. J. et al. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey - Outpatient Department data collected by the U. S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol 2005; 153 (6): 1176-1181.

76. Aroni K., Tsagroni E., Kavantzas N. et al. A study of the pathogenesis of Rosacea: How angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res 200; 300: 125-131.

77. Cribier B. Pathophysiology of rosacea: Redness, telangiectasia, and rosacea. Ann Dermatol Venereol 2011; 138: 184-191.

78. Cribier B. Rosacea under the microscope: Characteristic histological findings. J Eur Acad Dermatology Venereol 2013; 27: 1336-1343.

79. Aroni K., Tsagroni E., Lazaris A. C. et al. Rosacea: A clinicopathological approach. Dermatology 2004; 209: 177-182.

80. Aloi F., Tomasini C., Soro E. et al. The clinico-pathologic spectrum of rhinophyma. J Am Acad Dermatol 2000; 42: 468-472.

81. Tope W. D., Sangueza O. P. Rhinophyma’s fibrous variant. Histopathology and immuno-histochemistry. Am J Dermatopathol 1994; 16: 307-310.

82. Zouboulis C., Katsambas A., Kligman A. Pathogenesis and Treatment of Acne and Rosacea / ed. Zouboulis C. C., Katsambas A. D., Kligman A. M. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014.

83. Adams A. K., Davis J. L., Davis M. D. et al. What is your diagnosis? Granulomatous rosacea (Lupus miliaris disseminatus faciei, acne agminata). Cutis 2008; 82 (2): 103, 111-112.

84. Batra M., Bansal C., Tulsyan S. Granulomatous rosacea: Unusual presentation as solitary plaque. Dermatol Online J 2011; 17 (2): 9.

85. Pankina E. S., Arayijskaya E. R., Petrischev N. N. et al. Microcirculation in the patients with rosacea. Basic skin care as a part of complex therapy 2007; 9 (2): 79.

86. Wilkin J. Dahl M., Detmar M. et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 2002; 46 (4): 584-587.

87. Crawford G. H., Pelle M. T., James W. D. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-341.

88. Jansen T. Clinical presentations and classification of rosacea. Ann Dermatol Venereol 2011; 138: 192-200.

89. Jansen T., Plewig G. Rosacea: classification and treatment. J R Soc Med 1997; 90 (3): 144-150.

90. Rebora A. Rosacea. J Invest Dermatol 1987; 88 (3): 56-60.

91. Wilkin J. K. Rosacea. Pathophysiology and treatment. Arch Dermatol 1994; 130 (3): 359-362.

92. Wilkin J. K. Flushing reactions: Consequences and mechanisms. Ann Intern Med 1981; 95: 468-476.

93. Greaves M. W., Burova E. P. Flushing: causes, investigation and clinical consequences. J Eur Acad Dermatology Venereol 1997; 8 (2): 91-100.

94. Powell F. C. Clinical practice. Rosacea. N Engl J Med 2005; 352 (8): 793-803.

95. Wilkin J., Dahl M., Detmar M. et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2004; 50 (6): 907-912.

96. Berg M., Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989; 69: 419-423.

97. Pereira T. M., Vieira A. P., Basto A. S. Rosacea with extensive extrafacial lesions. Int J Dermatol 2008: 47: 52-55.

98. Wilkin J. K. Epigastric rosacea. Arch Dermatol 1980; 116: 584.

99. Hong E., Fischer G. Childhood ocular rosacea: Considerations for diagnosis and treatment. Australas J Dermatol 2009; 50: 272-275.

100. Chamaillard M., Mortemousque B., Boralevi F. et al. Cutaneous and ocular signs of childhood rosacea. Arch Dermatol 2008; 144: 167-171.

101. Ehmann L. M., Meller S., Homey B. [Successful treatment of granulomatous rosacea with dapsone]. Hautarzt 2013; 64: 226-228.

102. Messikh R., Try C., Bennani B. et al. [Efficacy of diuretics in the treatment of Morbihan’s disease: three cases]. Ann Dermatol Venereol 2012; 139: 559-563.

103. Ranu H., Lee J., Hee T. H. Successful treatment of Morbihan’s disease with oral prednisolone and doxycycline. Dermatol Ther 2010; 23: 682-685.

104. Lehmann P. [Rosacea: Clinical features and classification]. Hautarzt 2013; 64: 489-493.

105. Bhat Y. J., Manzoor S., Qayoom S. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol 2011; 56: 30-32.

106. Plewig G., Kligman A. M. ACNE and ROSACEA. Berlin, Heidelberg: Springer Berlin Heidelberg; 1993.

107. Vieira A. C., Mannis M. J. Ocular rosacea: Common and commonly missed. J Am Acad Dermatol 2013; 69: 36-41.

108. Oltz M., Check J. Rosacea and its ocular manifestations. Optometry 2011; 82: 92-103.

109. Lazaridou E., Fotiadou C., Ziakas N. G. et al. Clinical and laboratory study of ocular rosacea in northern Greece. J Eur Acad Dermatology Venereol 2011; 25: 1428-1431.

110. Samtsov A.V. Akne i akneformnye dermatozy: monografiya. M: Knizhnyy mir; 2009. [Самцов А.В. Акне и акнеформные дерматозы: монография // J. Cosmet. Dermatological Sci. Appl. М: ЮТКОМ, 2009. 287.]

111. Tuzum Y. et al. Rosacea and rhinophyma. Clin Dermatol 2014; 32 (1): 35-46.


Для цитирования:


Кубанова А.А., Махакова Ю.Б. Розацеа: распространенность, патогенез, особенности клинических проявлений. Вестник дерматологии и венерологии. 2015;(3):36-45. https://doi.org/10.25208/0042-4609-2015-0-3-36-45

For citation:


Kubanova A.A., Makhakova Y.B. Rosacea: prevalence, pathogenesis, particular features of clinical manifestations. Vestnik dermatologii i venerologii. 2015;(3):36-45. (In Russ.) https://doi.org/10.25208/0042-4609-2015-0-3-36-45

Просмотров: 380


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0042-4609 (Print)
ISSN 2313-6294 (Online)